These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18834370)

  • 1. Personal imports of drugs to Japan in 2005--an analysis of import certificates.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2008 Oct; 33(5):545-52. PubMed ID: 18834370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolving a double standard for risk management of thalidomide: an evaluation of two different risk management programmes in Japan.
    Ooba N; Sato T; Watanabe H; Kubota K
    Drug Saf; 2010 Jan; 33(1):35-45. PubMed ID: 20000865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Import for export; reporting and recordkeeping requirements for unapproved or violative products imported for further processing or incorporation and subsequent export--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(226):64930-7. PubMed ID: 10338872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Policy implications of drug importation.
    Palumbo FB; Mullins CD; Slagle AF; Rizer J
    Clin Ther; 2007 Dec; 29(12):2758-67. PubMed ID: 18201594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacotherapy of parasitic and tropical diseases in Japan].
    Maruyama H; Kimura M
    Nihon Rinsho; 2012 Dec; 70(12):2205-17. PubMed ID: 23259398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of an anticancer drug in Japan based on a new clinical trial system].
    Nakashima H; Nakano S
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FDA takes action against unapproved drugs.
    Meadows M
    FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Doctor-initiated clinical trials and the revised pharmaceutical affairs law].
    Takano T; Saijo N
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1391-7. PubMed ID: 14584270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the rejection probability in plant imports.
    Surkov IV; van der Werf W; van Kooten O; Lansink AG
    Phytopathology; 2008 Jun; 98(6):728-35. PubMed ID: 18944298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring differences in drug doses between Japan and Western countries.
    Arnold FL; Kusama M; Ono S
    Clin Pharmacol Ther; 2010 Jun; 87(6):714-20. PubMed ID: 20410879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The change of the new veterinary drug legislation for delivery of veterinary drugs].
    Schutte F
    Tijdschr Diergeneeskd; 2006 Jan; 131(2):54-5. PubMed ID: 16454094
    [No Abstract]   [Full Text] [Related]  

  • 17. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan.
    Malinowski HJ; Westelinck A; Sato J; Ong T
    J Clin Pharmacol; 2008 Aug; 48(8):900-8. PubMed ID: 18524997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.